ATE325621T1 - Il-12 als adjuvanz für bordetella pertussis impfstoffe - Google Patents

Il-12 als adjuvanz für bordetella pertussis impfstoffe

Info

Publication number
ATE325621T1
ATE325621T1 AT97932137T AT97932137T ATE325621T1 AT E325621 T1 ATE325621 T1 AT E325621T1 AT 97932137 T AT97932137 T AT 97932137T AT 97932137 T AT97932137 T AT 97932137T AT E325621 T1 ATE325621 T1 AT E325621T1
Authority
AT
Austria
Prior art keywords
adjuvance
bordetella pertussis
pertussis vaccines
vaccines
bordetella
Prior art date
Application number
AT97932137T
Other languages
English (en)
Inventor
Kingston H G Mills
Bernard P Mahon
Mark S Ryan
Fiona Griffin
Original Assignee
Nat Univ Ireland Maynooth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Ireland Maynooth filed Critical Nat Univ Ireland Maynooth
Application granted granted Critical
Publication of ATE325621T1 publication Critical patent/ATE325621T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97932137T 1996-05-31 1997-05-30 Il-12 als adjuvanz für bordetella pertussis impfstoffe ATE325621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1587196P 1996-05-31 1996-05-31
US82986597A 1997-03-31 1997-03-31

Publications (1)

Publication Number Publication Date
ATE325621T1 true ATE325621T1 (de) 2006-06-15

Family

ID=26687907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97932137T ATE325621T1 (de) 1996-05-31 1997-05-30 Il-12 als adjuvanz für bordetella pertussis impfstoffe

Country Status (10)

Country Link
US (5) US6929794B1 (de)
EP (2) EP1015026B1 (de)
JP (2) JP3737519B2 (de)
AT (1) ATE325621T1 (de)
AU (1) AU724743B2 (de)
DE (1) DE69735856T2 (de)
DK (1) DK1015026T3 (de)
ES (1) ES2262181T3 (de)
PT (1) PT1015026E (de)
WO (1) WO1997045139A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325621T1 (de) * 1996-05-31 2006-06-15 Nat Univ Ireland Maynooth Il-12 als adjuvanz für bordetella pertussis impfstoffe
EP1053015A2 (de) * 1998-02-12 2000-11-22 American Cyanamid Company Mit interleukin-12 formulierten pneumokokkus und meningokokkus impfstoffen
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
AU747917B2 (en) * 1998-03-05 2002-05-30 Medical College Of Ohio, The Enhancement of immunity by intranasal inoculation of IL-12
US7611721B1 (en) 1999-05-13 2009-11-03 Wyeth Holdings Corporation Adjuvant combination formulations
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
CN1437481A (zh) * 2000-06-22 2003-08-20 美国氰胺公司 作为佐剂组合的qs－21和il－12
PE20020530A1 (es) * 2000-11-10 2002-06-18 Wyeth Corp Formulaciones de combinacion adyuvante
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
US20080138833A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
PT2670432T (pt) * 2011-02-04 2021-05-04 Zoetis Services Llc Composições imunogénicas de bordetella bronchiseptica
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
US4705686A (en) * 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
JPH01193231A (ja) * 1988-01-27 1989-08-03 Takeda Chem Ind Ltd 抗腫瘍剤
ATE140483T1 (de) 1988-11-10 1996-08-15 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
US5162223A (en) * 1989-02-17 1992-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Resources Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis
AU648509B2 (en) * 1989-07-14 1994-04-28 Wyeth Holdings Corporation Stable vaccine compositions containing interleukins
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
EP0653943A4 (de) 1992-07-13 1996-10-02 Baylor College Medicine Eine somatische gentherapie auf gelenke zielend.
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
DE69529219T2 (de) 1994-07-01 2003-11-06 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Helicobacter proteine und impstoffe
AU3735095A (en) 1994-09-30 1996-04-26 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
JP3939752B2 (ja) * 1994-10-05 2007-07-04 バンダービルト ユニバーシティー パラミクソウイルスワクチン用アジュバントとしてのインターロイキン−１２
WO1997000321A1 (en) 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
ATE325621T1 (de) * 1996-05-31 2006-06-15 Nat Univ Ireland Maynooth Il-12 als adjuvanz für bordetella pertussis impfstoffe

Also Published As

Publication number Publication date
AU724743B2 (en) 2000-09-28
EP1649868A1 (de) 2006-04-26
DE69735856T2 (de) 2006-11-16
WO1997045139A2 (en) 1997-12-04
US20060263379A1 (en) 2006-11-23
US20050158276A1 (en) 2005-07-21
PT1015026E (pt) 2006-08-31
DE69735856D1 (de) 2006-06-14
JP2001527516A (ja) 2001-12-25
DK1015026T3 (da) 2006-09-11
ES2262181T3 (es) 2006-11-16
JP2005112865A (ja) 2005-04-28
US6929794B1 (en) 2005-08-16
US20060263380A1 (en) 2006-11-23
JP3737519B2 (ja) 2006-01-18
AU3567097A (en) 1998-01-05
WO1997045139A3 (en) 1998-02-12
EP1015026A2 (de) 2000-07-05
US20060257419A1 (en) 2006-11-16
EP1015026B1 (de) 2006-05-10

Similar Documents

Publication Publication Date Title
DE69735856D1 (de) Il-12 als adjuvanz für bordetella pertussis impfstoffe
ITRM940376A0 (it) Dispositivo di controllo del funzionamento di un condizionatore d'ariae metodo per questo scopo.
NO975716D0 (no) Imidazolforbindelser
GB9713156D0 (en) Vaccines
NL300404I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
DE69930166D1 (de) Verfahren und zusammensetzungen für impfung mit dem pseudomonas aeruginosa v-antigen
NO1997010I1 (no) Bordetella pertussis P69 antigen
FI893512L (fi) Bordetella pertussis-vaccin.
FI950740L (fi) Bordetella bronchiseptica-rokote
ITAN940011A0 (it) Dispositivo di arresto ammortizzato per serrande o tapparelle
FI914433A0 (fi) Gen som kodar ett 30 kilodaltons yttermembranprotein fraon bordetella pertussis.
ITAN940006V0 (it) Dispositivo di arresto ammortizzato per serrande o tapparelle
ITMI910371V0 (it) Canaletta ecologica per la risagomatura di fossi, o similari, e per la correzione della pendenza di questi ultimi
DE69128095D1 (de) Azelluläre impfstoffe
IT9047612A0 (it) Dispositivo di ancoraggio di protesi dentarie e suo metodo di installazione.
TR28707A (tr) Oda spreyi yayma düzenegi.
IT9020880A0 (it) Dispositivo e metodo per la proiezione di diapositive.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1015026

Country of ref document: EP

REN Ceased due to non-payment of the annual fee